Top Story

Fenofibrate slows diabetic retinopathy progression in at-risk patients

September 2, 2014

Intensive treatment of glycemia and dyslipidemia slowed the progression of diabetic retinopathy in diabetic patients with cardiovascular disease or associated risk factors, according to study findings.

Data were culled from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, a collection of three randomized clinical trials designed to evaluate the effects of intensive blood glucose and blood pressure control and a combination of fenofibrate and statin vs. statin monotherapy therapy for dyslipidemia on the incidence of cardiovascular disease in patients with type 2 diabetes.

Allergan responds to Valeant, Pershing Square counterclaims

September 2, 2014
Allergan has filed an answer in the U.S. District Court for the Central District of California in response to Valeant Pharmaceuticals and Pershing Square Capital…
Breaking News

Ozurdex approved in EU for treatment of DME

September 2, 2014
The European Commission has extended marketing authorization for Ozurdex for the treatment of diabetic macular edema in certain patients, according to an Allergan press…
figure The Dry EyePublication Exclusive

Dry eye specialists should be on the lookout for ‘zebras’ in the summer

September 2, 2014
It is summertime in the northern latitudes, and all is well in the dry eye clinics of North America. Remember how hard it was to be a dry eye doc last winter during the…
More News Headlines »

Managing associate optometrists in your practice, part 4

July 31, 2014
As with eye surgeons, not all optometrists are created equally. It’s a broad but true generalization that younger…
More »
Meeting News Coverage Video

Speaker discusses HOME study

August 13, 2014
At the American Society of Retina Specialists meeting in San Diego, David S. Boyer, MD, discusses results from the HOME…
More »